Clinical guidelines on the management of hepatitis C

Booth, J; O’Grady, John; Neuberger, James

doi:10.1136/gut.49.suppl_1.i1

Cited by 137 publications

(117 citation statements)

References 173 publications

(132 reference statements)

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…24 To date, there have been 3 generations of anti-HCV EIAs, with the first developed in 1990. It suffered from poor sensitivity and could not detect antibody prior to 4-6 months following initial infection.…”

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta‐analysis

Lehman

Wilson

2008

Intl Journal of Cancer

128

View full text Add to dashboard Cite

Liver cancers are strongly linked to hepatitis B virus (HBV) and hepatitis C virus (HCV). Egypt has the highest prevalence of HCV worldwide and has rising rates of hepatocellular carcinoma (HCC). Egypt's unique nature of liver disease presents questions regarding the distribution of HBV and HCV in the etiology of HCC. Accordingly, a systematic search of MEDLINE, ISI Web of Science, ScienceDirect and World Health Organisation databases was undertaken for relevant articles regarding HBV and HCV prevalence in Egypt among healthy populations and HCC cases. We calculated weighted mean prevalences for HBV and HCV among the populations of interest and examined differences in prevalence by descriptive features, including age, year and geographic region. Prevalences for HBV and HCV were 6.7% and 13.9% among healthy populations, and 25.9% and 78.5% among HCC cases. Adults had higher prevalences of both infections (Adult HBV 5 8.0%, Child HBV 5 1.6%; Adult HCV 5 15.7%, Child HCV 5 4.0%). Geographically, HBV was higher in the south, whereas HCV was greater in the north (North HBV 5 4.6%, South HBV 5 11.7%; North HCV 5 15.8%, South HCV 5 6.7%). Among HCC cases, HBV significantly decreased over time (p 5 0.001) while HCV did not, suggesting a shift in the relative influences of these viruses in HCC etiology in Egypt. Our results highlight large amounts of heterogeneity among the epidemiological factors associated with liver disease in Egypt and underscore the necessity of an integrated strategy for the successful prevention of viral hepatitis infections and chronic liver disease. ' 2008 Wiley-Liss, Inc.Key words: pooled analysis; liver cancer; infectious diseases; developing countries Hepatocellular carcinoma (HCC) comprises nearly 6% of all incident cancer cases worldwide, with the overwhelming majority occurring in the developing world.1 One of the least curable malignancies, HCC is the third most frequent cause of cancer mortality among men worldwide.1 Chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) have been cited as, by far, the most important etiologic agents.2 According to the World Health Organisation (WHO), 350 million people are chronically infected with HBV and 170 million are infected with HCV.3,4 The relative importance of HBV and HCV as causative agents can vary greatly from region to region and over time.1,5 Selecting appropriate HCC prevention and control methods, therefore, depends on understanding the dynamics of these agents in a specified geographic region.Incidence of HCC in Egypt is currently increasing, which may be the result of a shift in the relative importance of HBV and HCV as primary risk factors.6-8 HCC is the second most frequent cause of cancer incidence and mortality among men in Egypt.9 Hospitalbased studies from Egypt have reported an increase in the relative frequency of all liver-related cancers in Egypt (>95% as HCC), from 4.0% in 1993 to 7.3% in 2003.6-8 The Middle East Cancer Consortium recently reported that the incidence rate among males was 7 times greater...

show abstract

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta‐analysis

Lehman

Wilson

2008

Intl Journal of Cancer

128

View full text Add to dashboard Cite

show abstract

“…8 In view of the complexity of the therapeutic regime, the side effects and concerns that those who continue to inject may re-infect themselves, many authorities have advised that active injectors should not receive therapy; for example, the 2001 UK guidelines recommend that 'current intravenous drug users should not be treated'. 9 Attitudes to therapy in injectors have evolved 10 14 In these studies, patients with circumstances that were thought to reduce compliance (such as lack of a fixed abode) were excluded and thus compliance in socially challenged injecting drug users has not been assessed. This has led to diverse guidelines for the management of active injectors with hepatitis C 15 and it remains unclear who is likely to benefit from anti-viral therapy.…”

Section: Introductionmentioning

confidence: 99%

Community‐based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use

Wilkinson

Crawford

Tippet

et al. 2008

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The current treatment for HCV, according to the UK clinical guidelines, is with a combination therapy of two drugs, Interferon-alpha and Ribavirin [3]. A major factor in prescribing combination therapy is that both drugs produce side effects in most people [3]. The cost of combination therapy is between £3000 and £12000 per patient per year [3].…”

Section: Introductionmentioning

confidence: 99%

“…A major factor in prescribing combination therapy is that both drugs produce side effects in most people [3]. The cost of combination therapy is between £3000 and £12000 per patient per year [3]. It is generally thought that treating patients with expensive drugs with potentially serious side-effects may be inappropriate unless there is evidence of disease activity 1 .…”

Section: Introductionmentioning

confidence: 99%

“…This damage can be extremely serious, resulting in liver failure and death of the patient. The current treatment for HCV, according to the UK clinical guidelines, is with a combination therapy of two drugs, Interferon-alpha and Ribavirin [3]. A major factor in prescribing combination therapy is that both drugs produce side effects in most people [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An automated pattern recognition system for the quantification of inflammatory cells in hepatitis-C-infected liver biopsies

Hodgson

Harrison

Cross

2006

Image and Vision Computing

View full text Add to dashboard Cite

This paper presents an automated system for the quantification of inflammatory cells in hepatitis-C-infected liver biopsies. Initially, features are extracted from colour-corrected biopsy images at positions of interest identified by adaptive thresholding and clump decomposition. A sequential floating search method and principal component analysis are used to reduce dimensionality. Manually annotated training images allow supervised training. The performance of Gaussian parametric and mixture models is compared when used to classify regions as either inflammatory or healthy. The system is optimized using a response surface method that maximises the area under the receiver operating characteristic curve. This system is then tested on images previously ranked by a number of observers with varying levels of expertise. These results are compared to the automated system using Spearman rank correlation. Results show that this system can rank 15 test images, with varying degrees of inflammation, in strong agreement with five expert pathologists.

show abstract

Clinical guidelines on the management of hepatitis C

Cited by 137 publications

References 173 publications

Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta‐analysis

Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta‐analysis

Community‐based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use

An automated pattern recognition system for the quantification of inflammatory cells in hepatitis-C-infected liver biopsies

Contact Info

Product

Resources

About